Beactica will become known for creating breakthrough therapeutics that transform the prospects for patients suffering from life-threatening cancers
We create novel therapeutics that will benefit cancer patients across the world. We will bring hope to those patients and their families. We will impress the giants of the pharmaceutical industry with our scientific breakthroughs. We will succeed in selecting and targeting key disease proteins of vital importance for cancer. The name Beactica will be recognised to represent outstanding innovation and scientific excellence. We will be proud of how our hard work enabled Beactica to transition into a clinical-stage company. We will feel a tremendous satisfaction over the long-lasting impact that we have created, and the lives that we thereby touched.
To address genetically defined cancers with high unmet medical need by targeting synthetically lethal disease proteins with novel allosteric modulators and targeted protein degraders (PROTACs)
Sign up for the Beactica newsletter to receive our latest news and updates